Ardsley Advisory Partners LP Has $6.70 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Ardsley Advisory Partners LP cut its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 20.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 400,000 shares of the company’s stock after selling 100,000 shares during the quarter. Ardsley Advisory Partners LP’s holdings in Teva Pharmaceutical Industries were worth $6,704,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Advisors Asset Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $41,000. New Age Alpha Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $43,000. Sound Income Strategies LLC grew its position in Teva Pharmaceutical Industries by 3,715.8% during the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after purchasing an additional 2,824 shares in the last quarter. MAI Capital Management raised its stake in Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares during the period. Finally, Brooklyn Investment Group lifted its holdings in shares of Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock valued at $77,000 after purchasing an additional 4,014 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 0.8%

NYSE:TEVA opened at $28.56 on Wednesday. The company has a market capitalization of $32.75 billion, a P/E ratio of 47.59, a P/E/G ratio of 1.52 and a beta of 0.67. The stock’s 50 day moving average price is $22.83 and its 200 day moving average price is $19.37. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $29.10.

Insider Buying and Selling

In other news, Director Roberto Mignone sold 200,000 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director owned 495,000 shares in the company, valued at $11,934,450. This represents a 28.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently commented on the company. Bank of America raised their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays assumed coverage on Teva Pharmaceutical Industries in a research report on Tuesday. They set an “overweight” rating and a $35.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus price target of $30.25.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.